Ibalizumab is a humanized anti-CD4 monoclonal antibody approved for the treatment of HIV-1 infection. Ibalizumab blocks HIV-1 entry into CD4 cells while preserving normal immune function.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.